Distinct transcriptomic signature of mRNA and microRNA in

1 ulcerative colitis and irritable bowel syndrome 2 Hanqing Luo^{1,2}, Jiacheng Dai^{3,4}, Chunyu Liu^{3,5}, Yue Lee¹, Hong Lv¹, Jiaming 3 Oian^{1*} 4 ¹Department of Gastroenterology, Peking Union Medical College Hospital, 5 Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China 6 ²Department of Health Care, Peking Union Medical College Hospital, Chinese 7 Academy of Medical Science, Peking Union Medical College, Beijing, China 8 ³ Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, 9 School of Life Sciences, Central South University, Changsha, Hunan, China 10 ⁴ State Key Laboratory of Genetic Engineering, Human Phenome Institute, and 11 12 School of Life Sciences, Fudan University, Shanghai, China ⁵ Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, 13 USA 14 15 *corresponding author 16 Email: qianjiaming@126.com 17 Address: Department of Gastroenterology, Peking Union Medical College 18 Hospital, ShuaiFuyuan No.1, Dongcheng District, Beijing, China, 100730 19 20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21

22

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

ABSTRACTS Background: Ulcerative colitis (UC) and irritable bowel syndrome (IBS) are both chronic bowel diseases involving stress. To identify genes differentially expressed in UC and IBS, and to determine whether psychological stress can influence those gene expressions, we conducted this pilot study. Methods: Patients of UC, irritable bowel syndrome (IBS) and normal controls (NC) (n=5 in each group) were recruited. Perceived stress scale (PSS) was adopted to assess psychological stress level. Sigmoid mucosa samples were collected during colonoscopy. Differentially expressed genes (DEGs) of both mRNA and microRNA (DEG-mRNA and DEG-miRNA) were identified by RNA-Seq and microarray, respectively. Weighted gene co-expression network analysis (WGCNA), gene ontology, and microRNA target analysis were performed to identify regulatory relationships and pathways involved. Pearson correlation was performed to identify the relationship between DEGs and PSS score. Results: In total, 1,770 and 938 DEG-mRNAs, 107 and 3 DEG-miRNAs were identified in UC and IBS (nominal P<0.05), respectively. The transcriptome changes in UC and IBS were highly correlated but transcriptome severity was larger in UC. There were 268 overlapped DEG-mRNAs and 3 overlapped DEG-miRNAs between UC and IBS. Median PSS score was 27.5 (24.7, 40.0) in UC, 27.0 (17.5, 32.5) in IBS and 22.0 (12.0, 28.5) in NC. Five of the UC's DEG-mRNAs were significantly correlated to PSS scores, including SLC4A7, PLCB1, SPATA33, DECR2, RP11-792A8.4. There were no

DEGs correlate with PSS scores in IBS. One module enriched for immunological

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

pathways was upregulated in UC. Metabolic pathways were enriched in IBS. Within the UC-related co-expression module, we identified 18 DEG-mRNAs that were also targets of DEG-miRNA. Conclusions: Integration of microRNA and mRNA expression profiles identified changes of gene expression in both UC and IBS. Although the two diseases have significant overlapped transcriptomic changes, they have distinct signature. Immunological pathways are involved prominently in UC while metabolic pathways in IBS. Psychological stress is uniquely associated with the transcriptome changes of UC. **Keywords** ulcerative colitis; irritable bowel syndrome; stress; mRNAs; microRNAs **BACKGROUND** Ulcerative colitis (UC) is a kind of inflammatory bowel disease (IBD). It is characterized by chronic mucosal inflammation, with symptoms such as diarrhea and rectal bleeding. Irritable bowel syndrome (IBS) is a kind of functional gastrointestinal disease with symptoms including abdominal pain, diarrhea or constipation. Some published literatures have shown that IBD and IBS have overlapped features. Stress is gradually recognized as a factor in the development of UC (1, 2). In IBS, psychological stress plays a major role in the etiology through brain-gut axis (3). However, the etiology of both diseases is unknown. As genome-wide-associations studies (GWAS) became available, more than two

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

hundred genetic risk loci had been identified for IBD (4, 5). Several genomic regions had also been identified for IBS (6). Transcriptome studies, including both mRNA and microRNA, have contributed to our understanding of IBD and IBS pathogenesis(7, 8). A lot of mRNAs, such as HLA-DRB1 and TAP2, have been found to be differentially expressed in the colon of UC(9). A number of miRNAs, as modulators of gene expression, have been found to be involved in the initiation, development and progression of UC, such as miR-21(10), miR-31(11). In IBS, there were also some mRNA and microRNA found to be differentially expressed, such as INADL (12)and miR-16 (13). However, it is hard to pinpoint exact risk genes for those polygenic diseases. Network analysis may shed new light to the disease mechanisms. There are studies combining mRNA and miRNA profiles to identified molecular mechanisms in UC (14, 15). The analysis which paired miRNA-mRNA was also used to identify potential candidates in IBS (16). However, few studies compared transcriptomic signature in UC and IBS to date. Therefore, we hypothesize that miRNA-mRNA co-expression network and comparing transcriptome study will lead to better understanding of the core mechanisms of these two diseases with similar symptoms, UC and IBS. In this study, we aim to compare the transcriptome changes in UC and IBS, and their connections with psychological stress and immune changes to reveal their distinct and shared mechanisms. We performed this pilot transcriptome study with both mRNA and miRNA in UC and IBS. Differential expression analysis and weighted gene coexpression network analysis (WGCNA) were performed.

METHODS

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

1.1 Patients and Controls

The study protocols were submitted to, and approved by the ethics committee of Peking Union Medical College Hospital (PUMCH). The approval number was S-723. Patients and Controls were prospectively recruited. Ulcerative patients were diagnosed using established criteria (17). IBS patients were diagnosed by ROME III criteria (18). A normal control (NC) was defined as being asymptomatic, undergoing colonoscopy examination for routine check-up and no abnormality was found under colonoscopy. Further criteria were as follows. Inclusion criteria: age between 16 and 80 years old; UC or IBS diagnosis confirmed by gastroenterology physicians of PUMCH; signed informed consent. Exclusion criteria: past total colorectal resection; comorbidity with severe physical or mental illness, such as heart failure, schizophrenia and major depressive disorder; any other contraindications for colonoscopy; UC patients without the presence of inflammation in the sigmoid colon; self-reported difficulties in reading or understanding. In this pilot study, 5 UC patients, 5 IBS patients and 5 NC were recruited.

1.2 Data and questionnaire collection

Data on demographics (age, gender) and degree of inflammation in UC patients were collected. In UC patients, inflammation of sigmoid mucosa was evaluated

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

according to Mayo scores (19) under colonoscopy. Briefly, active inflammation was scored 0 as no inflammation, 1 as obscure texture of the blood vessel, 2 as loss of texture of the blood vessel, and 3 as ulceration and spontaneous bleeding. All of the participators were asked to fill a questionnaire to assess their perceived stress in the last month. Version PSS-14 of the Perceived Stress Scale (PSS) (20) was used. PSS-14 is a 14-item questionnaire, focusing on the feelings of stress and handling of stress during the preceding month. The higher the PSS score, the greater the perceived stress. Its psychometric properties have been validated in a Chinese population (21). 1.3 Tissue Collection and RNA extraction Biopsies were taken from the most affected part in sigmoid or from the middle of the sigmoid if there was no evidence of inflammation. A single endoscopist was arranged to perform colonoscopy, take biopsies and assess the degree of inflammation. Biopsies were immediately stored in the RNAlater® (Ambion, Inc., Austin, TX) at 4°C for the first 24 hours, and then frozen and kept at -80°C until RNA extraction. Total RNA was extracted from frozen biopsies using Trizol® (Invitrogen, Carlsbad, CA) according to a standard protocol. Sample quality was assessed by both a photospectrometer (Nano Drop Technologies®, Thermo Scientific, Wilmington, DE) and Agilent 2100 Bioanalyzer. The 260/280 ratios in all samples were between 1.8 to 2.0, and the RNA integrity number (RIN) were ≥7. Total RNA was required to be more than 1µg before miRNA chip examination.

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

1.4 Message RNA Sequencing and small RNA chip examination Message RNA (mRNA) sequencing library was built for each sample by using KAPA Stranded mRNA-Seq Kit Illumina® platform (KAPA BIOSYSTEMAS). mRNA libraries were sequenced on the HiSeq2500 (Illumina) following the manufacturer's protocol. The sequencing data generated in this study can be downloaded from the NCBI SRA database at https://www.ncbi.nlm.nih.gov/sra/PRJNA674301. Affymetrix Genechip miRNA4.0 Array was used to detect the miRNAs. The probe sequences covered all the mature miRNA in the miRbase V20 and small nuclear RNAs (snoRNAs and scaRNAs) of humans. Total RNA was labeled with FlashTagTM Biotin RNA Labeling Kit. After labeling, gene chip hybridization reaction, and scanning, Affymetrix® GeneChip® Command Console® Software (AGCC) was used to save the chip's fluorescent scanning image into a .DAT file for further analyses. The microarray downloaded data be from the **NCBI GEO** database can at http://www.ncbi.nlm.nih.gov/geo/ using accession number GSE160900. 1.5 Statistical Methods and Bioinformatics 1.5.1 Data preprocessing For mRNA data, we profiled 57,821 genes from the 15 samples. Expression levels were quantified with counts by Robust Structural Equation Modeling (RSEM). We normalized expression with gene length and used transcripts per million (TPM) as expression value for downstream analyses. Genes were filtered to include those with

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

TPM > 0.1 in at least 20% samples. After filtering, 17,895 genes were remained. For miRNA data, we profiled 4,575 probes from the 15 samples. The miRNA probes absent in at least 20% samples were filtered and left 852 miRNAs for downstream analyses. mRNA and miRNA data were combined for differential gene expression analysis and gene co-expression network analysis. Log2 transformed data of RNA-seq and miRNA microarray was quantile normalized, separately (22). The expression level of mRNA data and miRNA data is distributed in the same scale. After that, we combined mRNA data and miRNA data in one data matrix for further analysis. Principle component analysis (PCA) plot and clustering plot were evaluated for sample outliers with one sample excluded. 1.5.2 Wilcoxon signed-rank test for differential expression analysis To detect individual mRNA and miRNAs that differentially expressed in patients and NC, we performed Wilcoxon signed-rank test for differential expression analysis using R. UC samples versus NC and IBS samples versus NC were performed by Wilcoxon signed-rank test. Log2 fold-change (log2FC) of mRNA and miRNA was calculated. Finally, we corrected for multiple testing using false discovery rate (FDR) correction. We compared overlapped differentially expressed genes and miRNAs in two diseases with ggplot2 package. The association between differentially expressed genes (DEGs) and PSS scores were evaluated by Pearson correlation analysis. 1.5.3 Gene co-expression network analysis To evaluate gene expression relationship of individual genes and miRNAs, we

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

perpetuity.
All rights reserved. No reuse allowed without permission.

performed Weighted Gene Co-expression Network Analysis (WGCNA) (23). Network analysis was performed with the WGCNA package using unsigned networks. A softthreshold power of 14 was used for all samples to construct scale-free topology (R²>0.8). Networks were constructed using the blockwiseModules function. Modules were summarized by their first principle component (ME, module eigengene), and defined using Pearson correlation. Genes within each module were prioritized based on their module membership (kME), defined as correlation to the module eigengene. Module-disease associations were evaluated using Pearson correlation, with UC and IBS versus controls, respectively. We also correlated modules with age, gender and PSS. The p-value of correlation were adjusted by FDR correction. 1.5.4 Gene ontology analysis We selected genes from modules which were significant different in disease versus NC, for gene ontology analysis. We used WebGastalt (WEB-based Gene SeT AnaLysis Toolkit) for gene functional enrichment analysis (24). 1.5.5 miRNA target overlap For miRNA in significant modules, we searched miRNA target gene from miRTarBase (25). We summarized the target genes that also have high kME in the same module. 1.5.6 DEG overlap with GWAS findings To evaluate whether the DEG has genetic basis, we compared the DEG results and gene co-expression modules with GWAS findings. We downloaded GWAS results of UC and IBS from GWAS Catalog (http://www.ebi.ac.uk/gwas/).

RESULTS

199

200

201

202

203

204


205

206

207

Differential expression

One UC patient was excluded because she was an outlier in PCA and cluster analysis (Fig. 1). The PCA plot and clustering result also indicate that there were no outliers among all the samples. The information of participants included in DEG and differentially expressed miRNA analysis was given in table 1.






Fig.1 The plot of clustering and principle component analysis (PCA) of all participants. Each participant is represented by each number. A: UC05 was excluded because the height of clustering showed this sample was an outlier. B: UC05 was not gather together with other samples, which was same as clustering result.

Table 1 The characteristics of participants in final analyses.

	UC (n=4)	IBS (n=5)	NC (n=5)
Male, n	3	3	3
Age*	35.5 (24.3, 47.5)	38.0 (28.5, 48.0)	44.0 (40.5, 52.0)

PSS score*	27.5 (24.7, 40.0)	27.0 (17.5, 32.5)	22.0 (12.0, 28.5)	

*Values are median (interquartile range). UC: ulcerative colitis, IBS: irritable bowel syndrome, NC: normal control, PSS: perceived stress scale, n: number.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225


Comparing with NC, there were 1770 DEGs and 107 differentially expressed miRNAs in UC patients, 938 DEGs and 3 differentially expressed miRNAs in IBS patients by nominal P<0.05. However, after multiple testing correction, none of the DEGs or differentially expressed miRNAs was significant according to FDR of P<0.05. Five of the DEGs were related to PSS scores in UC with P <0.01, including SLC4A7 (p=0.94), PLCB1 (p=0.92), SPATA33 (p=-0.90), DECR2 (p=-0.88), RP11-792A8.4 (p=-0.87). There were no DEGs correlate with PSS scores in IBS. In UC and IBS, there were 268 overlapped DEGs. Majority of the DEGs (263) had consistent change in the two diseases. Only five genes were upregulated in IBS but downregulated in UC. Among these shared genes, AHR, GPR18, CD28, FAM26F, AC019330.1, LYRM9 are part of GWAS signals in UC. AC019330.1 and LYRM9 were both downregulated in UC and IBS, while others were upregulated in UC and IBS. The regression slopes of UC and IBS fold change relative to control is 0.85. This plot indicated that these two diseases have many similar gene changes in the same

direction, and the transcriptomic severity was larger in UC than in IBS (Fig.2).

Fig.2 The regression slopes of UC and IBS fold change effect size. The green line shows the slope is 0.85, indicating the transcriptomic severity was larger in UC than in IBS. Values are log2 transformed fold change of differential expressed gene (UC vs control or IBS vs

IBS represent disease-related gene co-expression module.


control).



Gene co-expression network and gene ontology analysis in UC and IBS patients

In the co-expression network analysis, we identified 44 modules (Fig.3). Based on Eigengene differential analysis, Module 6 (FDR-corrected p=0.04) and 11 (FDR-corrected p=0.02) were identified as significantly different in UC versus NC. Module 15 (FDR-corrected p=0.08) and 2 (FDR-corrected p=0.08) were different between IBS and NC (Fig.4). Module 6 and 15 were upregulated in diseases, while module 11 and 2 were suppressed. No significant correlation was detected between any of these modules and PSS scores.

Fig.3 Network dendrogram from co-expression topological overlap of genes in WGCNA. Color bars show gene co-expression modules. Different colors represent different modules. Color bars of UC and



239

240

241

242

243


244

245

246

Fig. 4 Heatmap of gene co-expression module that correlate to disease state, gender or age of participants.

Values are Pearson correlation coefficient and q value (in the bracket) after multiple testing.



In the gene ontology annotation on these disease-associated modules, Module 6 was enriched for activation of immune response, immune response-regulating signaling pathway, leukocyte cell-cell adhesion and regulation of cell activation pathways. Module 15 was enriched for mitochondrial-related pathways. Module 2 was enriched

for DNA transcription and DNA metabolic regulation process.

Comparing UC to IBS showed a variety of classes of differential pathway regulation (Table 2). Leukocyte cell-cell adhesion pathway was found elevated in UC, but suppressed in IBS. Immune response is activated in UC. In contrast, pathways annotated as adaptive immune response and inflammatory response to antigenic stimulus were negatively regulated in IBS.

Table 2. Biological pathways in disease-related modules related to immune responses in UC and IBS.

Gene ontology enrichment	P	FDR	MODULE	UC	IBS
activation of immune response	< 0.001	< 0.001	6	↑	
immune response-regulating signaling pathway	< 0.001	< 0.001	6	↑	
	< 0.001	< 0.001	6	↑	
leukocyte cell-cell adhesion	0.002	0.173	2		\downarrow
regulation of cell activation	< 0.001	< 0.001	6	↑	
response to interferon-γ	< 0.001	< 0.001	6	↑	
regulation of cell-cell adhesion	< 0.001	< 0.001	6	↑	
leukocyte proliferation	< 0.001	< 0.001	6	↑	
response to type I interferon	< 0.001	< 0.001	6	↑	
response to virus	< 0.001	< 0.001	6	↑	
leukocyte differentiation	< 0.001	< 0.001	6	↑	
leukocyte apoptotic process	0.006	1	11	\downarrow	
Adaptive immune response	0.001	0.128	2		\downarrow
inflammatory response to antigenic stimulus	0.002	0.185	2		\downarrow

Arrows represent up or down-regulated in disease. UC: ulcerative colitis, IBS: irritable bowel syndrome

MiRNA targets overlap with genes in module 6

254

255

256

257

258

259

260

261

262

263

264

265

From WGCNA results, we identified module 6 in UC as a critical module. There were 13 miRNAs in this module. We focused on the miRNA target genes and found 98 target mRNA genes for these 13 miRNAs in module 6. Top 18 of target genes are close to hub of the module 6 ($p \le 0.0001$ & kME > 0.85) (Fig. 5).




Fig.5 The top gene targeted by high kME miRNA in module 6. Top 18 genes and their kME are provided. Values are module eigengene (kME), which represent the importance of one gene in the module.

DEG overlap with GWAS findings

Among the 1770 DEGs in UC patients, there were 65 genes overlap with GWAS findings. There were 32 overlapped genes in module 6, such as CIITA, IKZF3, LPXN,

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

TNFSF8. In UC, 5 DEG-mRNAs were part of GWAS signals and shared with IBS. However, they were not overlapped with GWAS signals of IBS. Indeed, we did not find any DEGs overlapped with GWAS findings in IBS. **DISCUSSION** In this pilot study, even though the sample size is small, the combined miRNA and mRNA expression profiling led to significant findings of upregulated module of gene co-expression and 18 key genes in UC that can survive FDR correction. We found the overall transcriptome changes in UC and IBS were similar with the same gene changes in the same direction, but the transcriptomic severity was larger in UC than in IBS. Psychological stress was only correlated with 5 DEG-mRNAs in UC, but not with coexpression modules or IBS. Firstly, based on WGCNA and gene ontology analysis, activation of the immune response, immune response-regulating signaling pathway, leukocyte cell-cell adhesion and regulation of cell activation pathways were detected as critical pathways upregulated in UC. The link between immunological process and UC is consistent with previous studies (26). By integrating miRNA and mRNA results, 18 genes were supposed be important in the pathogenesis of UC. In those genes, IKZF3 (27), CIITA (28), TNFSF8 (29), LPXN (30) were also enriched for GWAS signals. IKZF3 is important in the regulation of B lymphocyte proliferation and differentiation (31). Leupaxin (LPXN) can play an inhibitory role in BCR signaling and B cell function (32).

That indicates that B cells and adaptive immune system may play a critical role in UC

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

pathogenesis. A former study also identified potential pathways related with immune response in UC with combined data analysis of expression levels of mRNA and miRNA (14). However, the public microarray data of mRNA and miRNA they used were not received from same subjects. Another study used correlation analysis of miRNA and mRNA in 17 UC patients (15) resulted in 319 DEG-mRNAs overlapped with our results, including IKZF3 and TNFSF8. However, compared with correlation analysis, WGCNA used in our study is more efficient (23). Secondly, similar changes of DEGs were found in UC and IBS, but UC has more DEG and bigger changes. For a long period of time, IBS has been considered as a functional bowel disease without organic lesions. The rise of molecular biology leads to some molecular abnormalities being detected in IBS. Some published literatures have shown that IBD and IBS have overlapped features, such as dysbiosis in gut microbiota and increased mucosal serotonin availability (33). Our results provided important evidence for that shared DEGs may be the basis for the common features of these two diseases. However, UC has bigger changes as an organic disease. We detected opposite regulatory directions between UC and IBS in some immunological pathways. Immunological pathways were upregulated in UC, which was accordance with other studies (34). However, intestinal immune system seemed to be suppressed in IBS. This finding conflicts with other studies (35). Now that chronic stress can cause immunosuppression (36), immune system might be suppressed in some disease phase of IBS patients. In another way, chemotactic chemokines and proinflammatory cytokines were found higher in sera and stool samples of IBS (37).

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

However, the changes in transcriptomic level and protein level may be opposite. Therefore, in IBS, whether immune response is suppressed or activated and whether transcriptome and protein changes in the same direction need further research. Thirdly, our results also give a glimpse on a possible link between psychological factors and UC. PSS scores were higher in UC patients compared with controls. We found 5 DEG-mRNAs correlated with PSS scores in UC. Among the 5 DEG-mRNAs, SLC4A7 was also upregulated in IBS. As a member of solute carrier family, SLC4A7 encodes a sodium bicarbonate cotransporter serving as an ion channel in the epithelium. The activity of SLC4A7 is modulated by cystic fibrosis transmembrane conductance regulator (CFTR). Mutations in CFTR can lead to channelopathies with diarrhea (38). Ion channels may be important in gastrointestinal function and could be influenced by perceived stress. PSS scores were also higher in IBS patients. However, we did not detect any DEGs related with perceived stress in IBS. On the one hand, different subtypes of IBS, including constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D), have different degree of correlation with psychological factors (39). In Martínez C's study (16), they found significant relationship between miRNA-mRNAs expression and PSS scores in patients with IBS-D. A mixed patient group in this study may minimize the significance. On the other hand, psychological stress may regulate function of those genes, rather than directly impact on the expression level. IBS had co-expression modules enriched for metabolic pathways, such as mitochondrial transport, mitochondrial membrane organization and mitochondrial

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

translation. Mitochondrial function is a key player in coordinating cellular metabolism, immunity and stress response (40). Our results supported that mitochondrial related pathways might function as a core in the complex mechanisms of IBS. In summary, we performed a pilot study on gene expression and miRNA profiles of UC and IBS, and simultaneously utilizing WGCNA and miRNA target gene overlapping methods to identify core genes. The immunological pathways in UC were highlighted again. Mitochondrial related pathways were emphasized in IBS. Some immunological pathways seemed to play an inverse role between UC and IBS. Our research has some limitations. Primarily, as a pilot study, the sample size is small, leading to the insufficient statistical power to identify significant DEGs when stringent criteria applied. Nevertheless, we identified reasonable key genes by conducting WGCNA and miRNA analysis. Second, PSS may not precisely reflect the impact of stress on UC patients. In future study, objective testing for physiological markers of stress, such as salivary cortisol levels could be used. Third, due to the limitation of experimental cost, those key genes and pathways were not verified by a second technique and functional experiments. We also do not have another data to validate the overall findings. Additional experiments are warranted to confirm the findings of this study. **CONCLUSIONS** Overall transcriptome changes in UC and IBS were similar, but the transcriptomic

severity was larger in UC. By WGCNA and gene ontology analysis, it was indicated

perpetuity.
All rights reserved. No reuse allowed without permission.

that immunological mechanism might play a central role in UC's development, while

mitochondrial related pathways might be important in IBS. There was some sort of

association between perceived stress and UC.

LIST OF ABBREVIATIONS

354

355

356

357

358

UC Ulcerative colitis

IBS Irritable bowel syndrome

IBS-C Constipation-predominant IBSIBS-D Diarrhea-predominant IBSPSS Perceived stress scale

DEG Differentially expressed gene

mRNA Message RNA

miRNA microRNA

WGCNA Weighted gene co-expression network analysis

GO Gene ontology

GWAS Genome-wide-associations studies

IBD Inflammatory bowel disease

HLA-DRB1 Human leukocyte antigen-DR beta 1

TAP2 Transporter 2, ATP binding cassette subfamily B member

INADL InaD-like gene

PUMCH Peking Union Medical College Hospital

NC Normal control

RSEM Robust Structural Equation Modeling

TPM Transcripts per million

PCA Principle component analysis

Log2FC Log2 fold-change
FDR False discovery rate
ME Module eigengene

WebGastalt WEB-based Gene SeT AnaLysis Toolkit

IQR Interquartile range

SLC4A7 Solute carrier family 4 member 7

PLCB1 Phospholipase C Beta 1

SPATA33 Spermatogenesis Associated 33 DECR2 2,4-Dienoyl-CoA Reductase 2

RP11-792A8.4

AHR Aryl Hydrocarbon Receptor
GPR18 G Protein-Coupled Receptor 18

CD28 CD28 Molecule

FAM26F Family With Sequence Similarity 26, Member F

AC019330.1 LYRM9 LYR Motif Containing 9 VCAM1 Vascular Cell Adhesion Molecule 1 TNFSF8 Tumor Necrosis Factor (Ligand) Superfamily, Member 8 TNFSF14 Tumor Necrosis Factor (Ligand) Superfamily, Member 14 STAT2 Signal Transducer And Activator Of Transcription 2 SP140L SP140 Nuclear Body Protein Like PPP1R16B Protein Phosphatase 1 Regulatory Subunit 16B LPXN Leupaxin LILRB2 Leukocyte Immunoglobulin Like Receptor B2 IKZF3 **IKAROS Family Zinc Finger 3** GNB4 G Protein Subunit Beta 4 DUSP2 **Dual Specificity Phosphatase 2 CYTIP** Cytohesin 1 Interacting Protein CLEC7A C-Type Lectin Domain Containing 7A CIITA Class II Major Histocompatibility Complex Transactivator CD274 CD274 Molecule (同时也是 PD-L1) CD180 CD180 Molecule CARD8 Caspase Recruitment Domain Family Member 8 APOL2 Apolipoprotein L2 **CFTR** Cystic fibrosis transmembrane conductance regulator

DECLARATIONS

359

360

361

362

363

364

365

366

367

368

369

370

Ethics approval and consent to participate

The study protocols were submitted to, and approved by the ethics committee of Peking

Union Medical College Hospital (PUMCH). The approval number was S-723.

Informed consent was obtained from all subjects or, if subjects are under 18, from a

parent. All methods were carried out in accordance with relevant guidelines and

regulations along with the approval.

Consent for publication

Not applicable

21

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

Availability of data and materials The sequencing data generated in this study has been deposited in the NCBI SRA database (https://www.ncbi.nlm.nih.gov/sra/PRJNA674301). **Competing interests** The authors declare that they have no competing interests. **Funding** This work was supported by Scientific research projects of public welfare industry (Grant No. 201002020, 201502005) and Medical science and health technology innovation projects of the Chinese academy of medical science (Grant No. 2016-I2M-3-001, 2019-I2M-2-007). **Authors' contributions** Han-Qing Luo performed the experiments and drafted the manuscript; Jia-Cheng Dai helped to analyze the data and prepare the figures; Chun-Yu Liu and Jia-Ming Qian edited and revised the manuscript; Han-Qing Luo, Yue Lee, Hong Lv and Jia-Ming Qian designed the research. All authors read and approved the final manuscript. Acknowledgements Not applicable

REFERENCES

- 1. Tabibian A, Tabibian JH, Beckman LJ, Raffals LL, Papadakis KA, Kane SV: Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Digestive diseases and sciences 2015, **60**(5):1366-1374.
- 2. Engler H, Elsenbruch S, Rebernik L, Kocke J, Cramer H, Schols M, Langhorst J: Stress burden and neuroendocrine regulation of cytokine production in patients with ulcerative colitis in remission. *Psychoneuroendocrinology* 2018, **98**:101-107.
- 3. Pellissier S, Bonaz B: The Place of Stress and Emotions in the Irritable Bowel Syndrome. Vitamins and hormones 2017, 103:327-354.
- 4. Spekhorst LM, Visschedijk MC, Weersma RK, Festen EA: Down the line from genomewide association studies in inflammatory bowel disease: the resulting clinical benefits and the outlook for the future. Expert review of clinical immunology 2015, **11**(1):33-44.
- 5. Huang H, Fang M, Jostins L, Umicevic Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* 2017, **547**(7662):173-178.
- 6. Bonfiglio F, Henström M, Nag A, Hadizadeh F, Zheng T, Cenit MC, Tigchelaar E, Williams F, Reznichenko A, Ek WE et al. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 2018, 30(9):e13358.
- 7. Cao B, Zhou X, Ma J, Zhou W, Yang W, Fan D, Hong L: Role of MiRNAs in Inflammatory Bowel Disease. Digestive diseases and sciences 2017, 62(6):1426-1438.
- Camilleri M, Carlson P, Acosta A, Busciglio I, Nair AA, Gibbons SJ, Farrugia G, Klee EW: 8. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. American journal of physiology Gastrointestinal and liver physiology 2014, 306(12):G1089-1098.
- 9. Cheng B, Liang X, Wen Y, Li P, Zhang L, Ma M, Cheng S, Du Y, Liu L, Ding M et al: Integrative analysis of transcriptome-wide association study data and messenger RNA expression profiles identified candidate genes and pathways for inflammatory bowel disease. Journal of cellular biochemistry 2019, 120(9):14831-14837.
- 10. Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, Cook J, Harris CC, Gius D, Mitchell JB: Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009, 4(7):e6377.
- Whiteoak SR, Claridge A, Balendran CA, Harris RJ, Gwiggner M, Bondanese VP, Erlandsson 11. F, Hansen MB, Cummings JRF, Sanchez-Elsner T: MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis? Inflammatory bowel diseases 2018, 24(11):2377-2385.
- 12. Camilleri M, Carlson P, Valentin N, Acosta A, O'Neill J, Eckert D, Dyer R, Na J, Klee EW, Murray JA: Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. American journal of physiology Gastrointestinal and liver physiology 2016, **311**(3):G365-376.
- 13. Wohlfarth C, Schmitteckert S, Härtle JD, Houghton LA, Dweep H, Fortea M, Assadi G, Braun

All rights reserved. No reuse allowed without permission.

- A, Mederer T, Pöhner S *et al*: miR-16 and miR-103 impact 5-HT(4) receptor signalling and correlate with symptom profile in irritable bowel syndrome. *Scientific reports* 2017, **7**(1):14680.
- 14. Yang L, Bian Y, Li Z, Yan Y, Li J, Li W, Zeng L: **Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis**. *Journal of gastrointestinal oncology* 2019, **10**(5):847-858.
- 15. Van der Goten J, Vanhove W, Lemaire K, Van Lommel L, Machiels K, Wollants WJ, De Preter V, De Hertogh G, Ferrante M, Van Assche G *et al.* Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. *PloS one* 2014, **9**(12):e116117.
- 16. Martínez C, Rodiño-Janeiro BK, Lobo B, Stanifer ML, Klaus B, Granzow M, González-Castro AM, Salvo-Romero E, Alonso-Cotoner C, Pigrau M *et al*: miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. *Gut* 2017, 66(9):1537-1538.
- 17. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P *et al.* Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extraintestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *Journal of Crohn's & colitis* 2017, 11(6):649-670.
- 18. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: **Functional bowel disorders**. *Gastroenterology* 2006, **130**(5):1480-1491.
- 19. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J *et al*: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007, **132**(2):763-786.
- 20. Cohen S, Kamarck T, Mermelstein R: **A global measure of perceived stress**. *J Health Soc Behav* 1983, **24**(4):385-396.
- 21. Leung DY, Lam TH, Chan SS: Three versions of Perceived Stress Scale: validation in a sample of Chinese cardiac patients who smoke. *BMC Public Health* 2010, **10**:513.
- 22. Bolstad BM, Irizarry RA, Astrand M, Speed TP: **A comparison of normalization methods for high density oligonucleotide array data based on variance and bias**. *Bioinformatics (Oxford, England)* 2003, **19**(2):185-193.
- 23. Langfelder P, Horvath S: **WGCNA:** an R package for weighted correlation network analysis. *BMC bioinformatics* 2008, **9**:559.
- 24. Wang J, Duncan D, Shi Z, Zhang B: **WEB-based GEne SeT Analysis Toolkit (WebGestalt): update 2013**. *Nucleic acids research* 2013, **41**(Web Server issue):W77-83.
- 25. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM *et al*: miRTarBase: a database curates experimentally validated microRNA-target interactions. *Nucleic acids research* 2011, **39**(Database issue):D163-169.
- 26. Choy MC, Visvanathan K, De Cruz P: **An Overview of the Innate and Adaptive Immune System in Inflammatory Bowel Disease**. *Inflammatory bowel diseases* 2017, **23**(1):2-13.
- 27. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG *et al*: **Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease**. *Nature genetics*

All rights reserved. No reuse allowed without permission.

- 2017, **49**(2):256-261.
- 28. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C *et al*: **Genome-wide association identifies multiple ulcerative colitis susceptibility loci**. *Nature genetics* 2010, **42**(4):332-337.
- 29. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A *et al.* **Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47**. *Nature genetics* 2011, **43**(3):246-252.
- 30. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hübenthal M *et al*. **Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci**. *Nature genetics* 2016, **48**(5):510-518.
- 31. Billot K, Parizot C, Arrouss I, Mazier D, Debre P, Rogner UC, Rebollo A: **Differential aiolos expression in human hematopoietic subpopulations**. *Leukemia research* 2010, **34**(3):289-293.
- 32. Chew V, Lam KP: Leupaxin negatively regulates B cell receptor signaling. *The Journal of biological chemistry* 2007, **282**(37):27181-27191.
- 33. Spiller R, Major G: **IBS and IBD separate entities or on a spectrum?** *Nature reviews Gastroenterology & hepatology* 2016, **13**(10):613-621.
- 34. Ramos GP, Papadakis KA: **Mechanisms of Disease: Inflammatory Bowel Diseases**. *Mayo Clinic proceedings* 2019, **94**(1):155-165.
- 35. Lazaridis N, Germanidis G: **Current insights into the innate immune system dysfunction** in irritable bowel syndrome. *Annals of gastroenterology* 2018, **31**(2):171-187.
- 36. Hou DD, Zhu RZ, Sun Z, Ma XD, Wang DC, Timothy H, Chen WN, Yan F, Lei P, Han XW *et al*: Serum Proteomics Analysis in Rats of Immunosuppression Induced by Chronic Stress. *Scandinavian journal of immunology* 2016, **84**(3):165-173.
- 37. Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL: **Chemotactic chemokines** are important in the pathogenesis of irritable bowel syndrome. *PloS one* 2014, **9**(3):e93144.
- 38. Beyder A, Farrugia G: **Ion channelopathies in functional GI disorders**. *American journal of physiology Gastrointestinal and liver physiology* 2016, **311**(4):G581-g586.
- 39. Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ: A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. *Alimentary pharmacology & therapeutics* 2014, **39**(4):426-437.
- 40. Rath E, Moschetta A, Haller D: **Mitochondrial function gatekeeper of intestinal epithelial cell homeostasis**. *Nature reviews Gastroenterology & hepatology* 2018, **15**(8):497-516.